IR-MED Honored with Prestigious Netty Award
IR-MED Inc. (“IR-MED” or the “Company”) (OTCQB:IRME), a pioneer in noninvasive artificial intelligence (AI) driven spectrographic analysis technology aimed at addressing critical healthcare needs, has earned recognition for its exceptional contributions. The Company was awarded the title of “Best Up-and-Coming Health Tech Company” at the Netty Awards for its innovative platform focused on “Sensing the Invisible.”
Understanding the Netty Awards
The Netty Awards are a celebration of excellence in the digital realm, recognizing outstanding companies and leaders across over 100 categories. These awards serve as a benchmark for quality, highlighting the creativity, innovation, and technical skill demonstrated by the winners.
Leadership Insights
Dr. Yaniv Cohen, Co-Founder and Chief Scientific Officer of IR-MED, expressed, "We are both proud and honored to receive recognition from the Netty Awards. Our dedicated team has invested years of effort and creativity into developing our platform technology, which we believe will significantly improve quality of life through the early detection of various medical conditions. The Best Up-and-Coming Health Tech Company award truly reflects our commitment and hard work."
Advancements in Technology
IR-MED’s award-winning entry showcases its innovative technology aimed at enhancing patient care. By equipping healthcare professionals with non-invasive, skin tone agnostic, real-time data-driven analysis of blood and tissue, the Company seeks to transform treatment approaches and economic models within multi-billion dollar markets.
Introducing the PressureSafe™ Device
Set to launch in the U.S. in the second half of 2024, PressureSafe™ is a handheld decision support device that accurately identifies early-stage pressure injuries. This groundbreaking solution addresses significant healthcare challenges while promoting equity in healthcare for individuals of all skin tones.
Looking Ahead: Future Products
IR-MED is also in the process of developing DiaSafe™, a decision support device aimed at detecting diabetic foot ulcers, with a planned launch in the second half of 2025. This device targets the growing global market for diabetic foot ulcer treatment, which is expected to expand significantly in the coming years.
About IR-MED Inc.
IR-MED Inc. is committed to developing a noninvasive spectrographic analysis technology platform that empowers healthcare professionals to detect, measure, and monitor various molecules in real-time without invasive procedures. PressureSafe is the first product in development, specifically designed for the early detection of pressure injuries, calibrated to each patient’s unique skin for precise results.
Innovations from the Company
IR-MED’s technology allows for accurate readings of biomarkers through a non-invasive approach, offering caregivers essential decision support in complex clinical situations. The Company holds patents that protect its innovations in noninvasive tissue analysis and the modeling of subcutaneous tissue. Currently, PressureSafe is undergoing usability studies at several medical centers.
Contact Information
Sharon Levkoviz, Chief Financial Officer
Tel: +972 (0) 4 6555054
Frequently Asked Questions
What was IR-MED recognized for at the Netty Awards?
IR-MED received the award for “Best Up-and-Coming Health Tech Company” due to its innovative healthcare technology.
What is the PressureSafe device?
PressureSafe is a handheld decision support device designed to accurately identify early-stage pressure injuries.
What future products is IR-MED developing?
IR-MED is working on DiaSafe, a device intended for diabetic foot ulcer detection, with a target launch in the second half of 2025.
How does IR-MED’s technology benefit healthcare providers?
The technology offers non-invasive, real-time data-driven analysis, which enhances decision-making for healthcare professionals.
Who can be contacted for more information about IR-MED?
For more information, you can reach out to Sharon Levkoviz, the Chief Financial Officer.
